Journal of Clinical Oncology
Articles in this Issue
Clinical outcomes of retroperitoneal lymph node dissection in patients with cT <sub>3–4</sub> N <sub>x</sub> M <sub>0</sub> non–clear cell renal cell carcinoma.
472 Background: Non–clear cell renal cell carcinoma (nccRCC) comprises 20–25% of renal cancers and exhibits distinct biolo...
A phase 1b/2 study to evaluate the safety and efficacy of igermetostat (XNW5004) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.
169 Background: Overexpression of EZH2 is associated with poor prognosis in patients (pts) with metastatic castration-resi...
Impact of neoadjuvant chemotherapy on perioperative outcomes following nephroureterectomy.
697 Background: Upper tract urothelial carcinoma (UTUC) is a urologic malignancy for which nephroureterectomy (NU) remains...
Beyond <i>BRCA</i> : Real-world outcomes with poly(ADP-ribose) polymerase inhibitors among patients with metastatic castration-resistant prostate cancer and homologous recombination repair mutations.
89 Background: Poly(ADP-ribose) polymerase inhibitors (PARPi) are established therapies for patients (pts) with metastatic...
Association of radiomic skeletal muscle features on prostate T1-weighted MRI with major adverse cardiac events in prostate cancer patients.
34 Background: Prostate cancer (PCa) is the most common malignancy among men, yet cardiovascular disease (CVD) remains a l...
RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC.
LBA631 Background: An estimated 60%-80% of patients (pts) with UC have HER2-expressing tumors. DV is an ADC comprising a n...
Improving access to clinical trial participation among underrepresented kidney cancer patients.
430 Background: It is well-studied that multiple barriers exist to oncology clinical trial participation. Patient (pt)-rel...
Topline results from BOND-003 cohort P: A multi-national, single-arm study of intravesical cretostimogene grenadenorepvec for treatment of high-risk, papillary only, BCG-unresponsive non-muscle invasive bladder cancer.
755 Background: Patients with High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer have limited treatment options...
Cardiovascular risk evaluation in men with prostate cancer study (CARE-PC): Pilot study to assess patient awareness and risk mitigation.
52 Background: Cardiovascular (CV) disease is a major cause of morbidity and mortality among patients (pts) with prostate...
Prognostic and predictive impact of HER-2 expression in metastatic urothelial carcinoma: Results from the single-centre BLADDHER study.
805 Background: Identifying novel therapeutic targets is a relevant clinical need in metastatic urothelial carcinoma (mUC)...
Real-world use of novel hormonal therapies in European and North American patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).
86 Background: Androgen receptor pathway inhibitors (ARPIs) are essential for mHSPC treatment; however, global use may var...
Effects of steroid pretreatment on adverse events and overall survival during enfortumab vedotin in urothelial carcinoma.
731 Background: Enfortumab vedotin (EV) is a standard subsequent therapy for patients with locally advanced or metastatic...
Ultra-sensitive molecular residual disease detection via tumor-informed whole-genome sequencing-based ctDNA assay in resectable urothelial cancer in the MONSTAR-SCREEN-3 project.
810 Background: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for detecting molecular residual diseas...
CORE-008 cohort B: Evaluating intravesical cretostimogene grenadenorepvec in patients with high-risk, BCG-exposed non-muscle invasive bladder cancer.
TPS896 Background: Patients with High-Risk NMIBC whose disease trajectory falls outside the strict FDA guidance of BCG-Unr...
Prospective monitoring of biochemically recurrent prostate cancer (BCR) using prostate specific membrane antigen (PSMA) imaging: 21-month follow-up.
37 Background: The use of PSMA imaging is impacting the management of BCR, but it remains unclear if treatment escalation...
Impact of FGFR3 alterations on first-line platinum based chemotherapy in patients with metastatic or locally advanced urothelial carcinoma: The retrospective IFUCA study.
735 Background: FGFR3 alterations are observed in 10–15% of patients with advanced urothelial carcinoma (UC). While target...
Primary urethral squamous cell carcinoma: Insights and outcomes from a 27-year institutional experience.
627 Background: Primary urethral cancer is one of the rarest cancers worldwide, resulting in limited data and ongoing deba...
Health-related quality of life, pain, and symptomatic skeletal events in the phase 3 PSMAddition study of [ <sup>177</sup> Lu]Lu-PSMA-617 ( <sup>177</sup> Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive mHSPC.
18 Background: In PSMAddition (NCT04720157), combining 177 Lu-PSMA-617 with ADT +...
FGFR-altered metastatic urothelial carcinoma in the real-world setting: Insight from the multicenter, prospective, non-interventional Italian registry of advanced/metastatic urothelial carcinoma (SATURNO)—A FICOG and Meet-URO study.
681 Background: The therapeutic landscape of metastatic Urothelial Carcinoma (mUC) is rapidly evolving, alongside increasi...
Real-world utilization and timing of initiation of bone-targeting agents (BTAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223: Results from Princess Margaret Cancer Centre (PM).
68 Background: Patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases treated with Radi...
Effect of tryptophan–serotonin–kynurenine pathways on immune landscape and survival in clear cell renal cell carcinoma: TCGA-KIRC transcriptomic analysis.
542 Background: Tryptophan metabolism regulates immune tolerance via the kynurenine (IDO1, TDO2) and serotonin (TPH1, HTRf...
Efficacy and safety of darolutamide and ADT in patient subgroups by baseline comorbidities and concomitant medications: ARANOTE <i>post hoc</i> analyses.
178 Background: Darolutamide (DARO) + androgen deprivation therapy (ADT) significantly improved radiological progression-f...
Serum amyloid A4 and cognitive functioning in long-term testicular germ cell tumor survivors.
606 Background: Long-term cognitive impairment has been described in survivors of testicular germ cell tumors (GCT) follow...
Tumor microenvironmental NRG1 activation of HER3 as a driver of resistance to PI3K pathway inhibition in prostate cancer.
263 Background: Despite the prevalence of phosphoinositide 3-kinase (PI3K) pathway alterations in prostate cancer (PCa), t...
Machine learning models combining <sup>68</sup> Ga-PSMA PET radiomics and clinical features to predict overall survival for mCRPC patients treated with <sup>177</sup> Lu-PSMA radioligand therapy.
215 Background: Metastatic castration-resistant prostate cancer (mCRPC) remains incurable despite recent therapeutic advan...